U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H38O6
Molecular Weight 446.5763
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HYDROCORTISONE VALERATE

SMILES

[H][C@@]12CC[C@](OC(=O)CCCC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]3([H])[C@@]2([H])CCC4=CC(=O)CC[C@]34C

InChI

InChIKey=FZCHYNWYXKICIO-FZNHGJLXSA-N
InChI=1S/C26H38O6/c1-4-5-6-22(31)32-26(21(30)15-27)12-10-19-18-8-7-16-13-17(28)9-11-24(16,2)23(18)20(29)14-25(19,26)3/h13,18-20,23,27,29H,4-12,14-15H2,1-3H3/t18-,19-,20-,23+,24-,25-,26-/m0/s1

HIDE SMILES / InChI

Molecular Formula C26H38O6
Molecular Weight 446.5763
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008697s032_33lbl.pdf

Hydrocortisone is the main glucocorticoid secreted by the adrenal cortex. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Hydrocortisone binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). Hydrocortisone is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.

CNS Activity

Curator's Comment: shown in dogs

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Cortef

Approved Use

CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

Launch Date

1952
Primary
Cortef

Approved Use

CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

Launch Date

1952
Palliative
Cortef

Approved Use

CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

Launch Date

1952
Primary
Cortef

Approved Use

CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

Launch Date

1952
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
258 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCORTISONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1162 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCORTISONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.82 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCORTISONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
9.9%
HYDROCORTISONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg 4 times / day multiple, intramuscular
Highest studied dose
Dose: 200 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 200 mg, 4 times / day
Sources:
unhealthy, 56 years (tange: 40-64 years)
n = 10
Health Status: unhealthy
Condition: primary adrenal insufficiency
Age Group: 56 years (tange: 40-64 years)
Sex: M+F
Population Size: 10
Sources:
200 mg 4 times / day multiple, intravenous
Highest studied dose
Dose: 200 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 4 times / day
Sources:
unhealthy, 56 years (tange: 40-64 years)
n = 10
Health Status: unhealthy
Condition: primary adrenal insufficiency
Age Group: 56 years (tange: 40-64 years)
Sex: M+F
Population Size: 10
Sources:
200 mg 4 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 4 times / day
Route: oral
Route: multiple
Dose: 200 mg, 4 times / day
Sources:
unhealthy, 56 years (tange: 40-64 years)
n = 10
Health Status: unhealthy
Condition: primary adrenal insufficiency
Age Group: 56 years (tange: 40-64 years)
Sex: M+F
Population Size: 10
Sources:
200 mg single, intravenous
Highest studied dose
Dose: 200 mg
Route: intravenous
Route: single
Dose: 200 mg
Sources:
unhealthy, 56 years (tange: 40-64 years)
n = 10
Health Status: unhealthy
Condition: primary adrenal insufficiency
Age Group: 56 years (tange: 40-64 years)
Sex: M+F
Population Size: 10
Sources:
2.5 % 4 times / day multiple, topical
Dose: 2.5 %, 4 times / day
Route: topical
Route: multiple
Dose: 2.5 %, 4 times / day
Sources:
unhealthy, adult
1 mg/kg 4 times / day multiple, intravenous
Dose: 1 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 mg/kg, 4 times / day
Sources:
unhealthy, children
n = 23
Health Status: unhealthy
Condition: vasoactive infusion
Age Group: children
Population Size: 23
Sources:
Other AEs: Infection...
Other AEs:
Infection (below serious, 6 patients)
Sources:
0.5 mg/kg 4 times / day multiple, intravenous
Dose: 0.5 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg/kg, 4 times / day
Sources:
unhealthy, neonate
n = 6
Health Status: unhealthy
Condition: Cardiovascular Insufficiency
Age Group: neonate
Population Size: 6
Sources:
Other AEs: Hyperbilirubinemia, Hypertension...
Other AEs:
Hyperbilirubinemia (serious, 1 patient)
Hypertension (serious, 1 patient)
Adrenal insufficiency (serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Infection below serious, 6 patients
1 mg/kg 4 times / day multiple, intravenous
Dose: 1 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 mg/kg, 4 times / day
Sources:
unhealthy, children
n = 23
Health Status: unhealthy
Condition: vasoactive infusion
Age Group: children
Population Size: 23
Sources:
Adrenal insufficiency serious, 1 patient
0.5 mg/kg 4 times / day multiple, intravenous
Dose: 0.5 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg/kg, 4 times / day
Sources:
unhealthy, neonate
n = 6
Health Status: unhealthy
Condition: Cardiovascular Insufficiency
Age Group: neonate
Population Size: 6
Sources:
Hyperbilirubinemia serious, 1 patient
0.5 mg/kg 4 times / day multiple, intravenous
Dose: 0.5 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg/kg, 4 times / day
Sources:
unhealthy, neonate
n = 6
Health Status: unhealthy
Condition: Cardiovascular Insufficiency
Age Group: neonate
Population Size: 6
Sources:
Hypertension serious, 1 patient
0.5 mg/kg 4 times / day multiple, intravenous
Dose: 0.5 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg/kg, 4 times / day
Sources:
unhealthy, neonate
n = 6
Health Status: unhealthy
Condition: Cardiovascular Insufficiency
Age Group: neonate
Population Size: 6
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Effect of ruminations on the saliva cortisol response to a social stressor.
2001 Apr
Enhanced memory for emotional material following stress-level cortisol treatment in humans.
2001 Apr
Individual differences in the diurnal cycle of salivary free cortisol: a replication of flattened cycles for some individuals.
2001 Apr
Lymphocyte responses to stress in postpartum women: relationship to vagal tone.
2001 Apr
Gender differences in age-related changes in HPA axis reactivity.
2001 Apr
Regulation of interleukin 1 beta RNA expression in the common carp, Cyprinus carpio L.
2001 Apr
Psychophysiological responses to the Stroop Task after a maximal cycle ergometry in elite sportsmen and physically active subjects.
2001 Feb
Circulatory support of the sick preterm infant.
2001 Feb
Interactions among paternal behavior, steroid hormones, and parental experience in male marmosets (Callithrix kuhlii).
2001 Feb
Menstrual cycle variation in spatial ability: relation to salivary cortisol levels.
2001 Feb
Modulation of P450 CYP3A4-dependent metabolism by P-glycoprotein: implications for P450 phenotyping.
2001 Feb
Glucocorticoids upregulate CD40 ligand expression and induce CD40L-dependent immunoglobulin isotype switching.
2001 Feb
Glucocorticoids protect against apoptosis induced by serum deprivation, cyclic adenosine 3',5'-monophosphate and p53 activation in immortalized human granulosa cells: involvement of Bcl-2.
2001 Feb
Regulation of phosphate uptake in primary cultured rabbit renal proximal tubule cells by glucocorticoids: evidence for nongenomic as well as genomic mechanisms.
2001 Feb
Plasma adrenocorticotropin and cortisol concentrations during acute hypoxemia after a reversible period of adverse intrauterine conditions in the ovine fetus during late gestation.
2001 Feb
Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome.
2001 Feb
The effects of epidural block on the distribution of lymphocyte subsets and natural-killer cell activity in patients with and without pain.
2001 Feb
Pulsatile growth hormone secretion decreases S-adenosylmethionine synthetase in rat liver.
2001 Feb
PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells.
2001 Feb
Urinary thromboxane, prostacyclin, cortisol, and 8-hydroxy-2'-deoxyguanosine in nonsmokers exposed and not exposed to environmental tobacco smoke.
2001 Feb
Postnatal glucocorticoids in very preterm infants: "the good, the bad, and the ugly"?
2001 Feb
Cooperative effects of STAT5 (signal transducer and activator of transcription 5) and C/EBPbeta (CCAAT/enhancer-binding protein-beta) on beta-casein gene transcription are mediated by the glucocorticoid receptor.
2001 Feb
Metabolic abnormalities in patients with adrenal incidentaloma.
2001 Feb
Is hydrocortisone clearance 50% slower in the evening than in the morning?
2001 Feb
Paraneoplastic hypercortisolism as a risk factor for severe infections in patients with malignant diseases.
2001 Feb
Cord blood leptin and insulin-like growth factor levels are independent predictors of fetal growth.
2001 Feb
Orexin A stimulates cortisol secretion from human adrenocortical cells through activation of the adenylate cyclase-dependent signaling cascade.
2001 Feb
Time course of 21-hydroxylase antibodies and long-term remission of subclinical autoimmune adrenalitis after corticosteroid therapy: case report.
2001 Feb
Aromatase p450 expression in a feminizing adrenal adenoma presenting as isosexual precocious puberty.
2001 Feb
Oral glucose augments the counterregulatory hormone response during insulin-induced hypoglycemia in humans.
2001 Feb
The patients with incidentally discovered adrenal adenoma (incidentaloma) are not at increased risk of osteoporosis.
2001 Feb
Food-dependent androgen and cortisol secretion by a gastric inhibitory polypeptide-receptor expressive adrenocortical adenoma leading to hirsutism and subclinical Cushing's syndrome: in vivo and in vitro studies.
2001 Feb
Human glucocorticoid feedback inhibition is reduced in older individuals: evening study.
2001 Feb
Troglitazone amplifies counterregulatory responses to hypoglycemia in nondiabetic subjects.
2001 Feb
Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy.
2001 Feb
Fertility and body composition after laparoscopic bilateral adrenalectomy in a 30-year-old female with congenital adrenal hyperplasia.
2001 Feb
Electrophysiological effects of corticosteroids on the retinal pigment epithelium.
2001 Feb
Green fluorescent protein mutant as label in homogeneous assays for biomolecules.
2001 Feb 1
Hormonal regulation of mitochondrial Tim23 gene expression in the mouse mammary gland.
2001 Feb 14
Carbachol induces homologous steroidogenic refractoriness of bovine fasciculata-reticularis cells.
2001 Feb 14
Thapsigargin inhibits angiogenesis in the rat isolated aorta: studies on the role of intracellular calcium pools.
2001 Feb 16
Post-dexamethasone cortisol level and memory performance in elderly depressed patients.
2001 Feb 2
Inhibition of cortisol secretion in dispersed head kidney cells of rainbow trout (Oncorhynchus mykiss) by endosulfan, an organochlorine pesticide.
2001 Jan
Human cervical tissue metabolizes the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, via alpha-hydroxylation and carbonyl reduction pathways.
2001 Jan
Neural correlates of maternal separation in rhesus monkeys.
2001 Jan 15
Crystallization of hydrocortisone acetate: influence of polymers.
2001 Jan 16
Monohydroxylation and esterification as determinants of the effects of cis- and trans-9-octadecenoic acids on the permeation of hydrocortisone and 5-fluorouracil across hairless mouse skin in vitro.
2001 Jan 16
Enzyme-mediated protection of the mineralocorticoid receptor against progesterone in the human kidney.
2001 Jan 22
The use of chitosan gels as matrices for electrically-modulated drug delivery.
2001 Jan 29
Patterns of integrin expression in a human mandibular explant model of osteoblast differentiation.
2001 Mar
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Many Hydrocortisone products are used topically https://www.drugs.com/pro/hydrocortisone.html
The initial dosage of CORTEF (Hydrocortisone) Tablets may vary from 20 mg to 240 mg of hydrocortisone per day depending on the specific disease entity being treated.
Route of Administration: Oral
Hydrocortisone concentration-dependently inhibited the current induced by 3 x 10(-5) M ACh with a half maximum inhibitory concentration (IC50) of 2.1 x 10(-4) M (in rats).
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:21:09 GMT 2023
Edited
by admin
on Fri Dec 15 15:21:09 GMT 2023
Record UNII
68717P8FUZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HYDROCORTISONE VALERATE
MART.   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
Hydrocortisone valerate [WHO-DD]
Common Name English
Cortisol 17-valerate
Common Name English
HYDROCORTISONE 17-VALERATE
MI  
Common Name English
HYDROCORTISONE 17-VALERATE [MI]
Common Name English
HYDROCORTISONE VALERATE [VANDF]
Common Name English
11.BETA.,17,21-TRIHYDROXYPREGN-4-ENE-3,20-DIONE 17-VALERATE
Systematic Name English
HYDROCORTISONE VALERATE [USP MONOGRAPH]
Common Name English
HYDROCORTISONE VALERATE [USAN]
Common Name English
HYDROCORTISONE VALERATE [MART.]
Common Name English
HYDROCORTISONE VALERATE [USP-RS]
Common Name English
NSC-759133
Code English
HYDROCORTISONE VALERATE [ORANGE BOOK]
Common Name English
WESTCORT
Brand Name English
PREGN-4-ENE-3,20-DIONE, 11,21-DIHYDROXY-17-((1-OXOPENTYL)OXY)-, (11.BETA.)-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C521
Created by admin on Fri Dec 15 15:21:09 GMT 2023 , Edited by admin on Fri Dec 15 15:21:09 GMT 2023
Code System Code Type Description
CAS
57524-89-7
Created by admin on Fri Dec 15 15:21:09 GMT 2023 , Edited by admin on Fri Dec 15 15:21:09 GMT 2023
PRIMARY
EPA CompTox
DTXSID9045633
Created by admin on Fri Dec 15 15:21:09 GMT 2023 , Edited by admin on Fri Dec 15 15:21:09 GMT 2023
PRIMARY
SMS_ID
100000086711
Created by admin on Fri Dec 15 15:21:09 GMT 2023 , Edited by admin on Fri Dec 15 15:21:09 GMT 2023
PRIMARY
CHEBI
50865
Created by admin on Fri Dec 15 15:21:09 GMT 2023 , Edited by admin on Fri Dec 15 15:21:09 GMT 2023
PRIMARY
PUBCHEM
5282494
Created by admin on Fri Dec 15 15:21:09 GMT 2023 , Edited by admin on Fri Dec 15 15:21:09 GMT 2023
PRIMARY
EVMPD
SUB02570MIG
Created by admin on Fri Dec 15 15:21:09 GMT 2023 , Edited by admin on Fri Dec 15 15:21:09 GMT 2023
PRIMARY
NCI_THESAURUS
C48024
Created by admin on Fri Dec 15 15:21:09 GMT 2023 , Edited by admin on Fri Dec 15 15:21:09 GMT 2023
PRIMARY
DRUG BANK
DB14544
Created by admin on Fri Dec 15 15:21:09 GMT 2023 , Edited by admin on Fri Dec 15 15:21:09 GMT 2023
PRIMARY
DRUG CENTRAL
4504
Created by admin on Fri Dec 15 15:21:09 GMT 2023 , Edited by admin on Fri Dec 15 15:21:09 GMT 2023
PRIMARY
FDA UNII
68717P8FUZ
Created by admin on Fri Dec 15 15:21:09 GMT 2023 , Edited by admin on Fri Dec 15 15:21:09 GMT 2023
PRIMARY
MESH
C038363
Created by admin on Fri Dec 15 15:21:09 GMT 2023 , Edited by admin on Fri Dec 15 15:21:09 GMT 2023
PRIMARY
RS_ITEM_NUM
1321004
Created by admin on Fri Dec 15 15:21:09 GMT 2023 , Edited by admin on Fri Dec 15 15:21:09 GMT 2023
PRIMARY
ECHA (EC/EINECS)
260-786-8
Created by admin on Fri Dec 15 15:21:09 GMT 2023 , Edited by admin on Fri Dec 15 15:21:09 GMT 2023
PRIMARY
WIKIPEDIA
Hydrocortisone valerate
Created by admin on Fri Dec 15 15:21:09 GMT 2023 , Edited by admin on Fri Dec 15 15:21:09 GMT 2023
PRIMARY
RXCUI
27199
Created by admin on Fri Dec 15 15:21:09 GMT 2023 , Edited by admin on Fri Dec 15 15:21:09 GMT 2023
PRIMARY RxNorm
ChEMBL
CHEMBL1200562
Created by admin on Fri Dec 15 15:21:09 GMT 2023 , Edited by admin on Fri Dec 15 15:21:09 GMT 2023
PRIMARY
DAILYMED
68717P8FUZ
Created by admin on Fri Dec 15 15:21:09 GMT 2023 , Edited by admin on Fri Dec 15 15:21:09 GMT 2023
PRIMARY
NSC
759133
Created by admin on Fri Dec 15 15:21:09 GMT 2023 , Edited by admin on Fri Dec 15 15:21:09 GMT 2023
PRIMARY
MERCK INDEX
m6094
Created by admin on Fri Dec 15 15:21:09 GMT 2023 , Edited by admin on Fri Dec 15 15:21:09 GMT 2023
PRIMARY Merck Index
Related Record Type Details
ACTIVE MOIETY